Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Kaplan-Meier survival analysis
The overall survival did not reach median. The median progression free... | Download Scientific Diagram
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports
Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram
Survival Analysis
Survival Analysis in R
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect
Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Opdualag™ (nivolumab and relatlimab-rmbw) Efficacy in Melanoma
TIBSOVO® (ivosidenib tablets) an IDH1 Inhibitor
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
primed.info
